Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2Completed 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1CNS 1

Conditions

Lymphoma, Non-Hodgkin 1Gliosarcoma 1Glioblastoma 1

Interventions

Specimen Handling 479pembrolizumab 454Magnetic Resonance Spectroscopy 421Carboplatin 327Cyclophosphamide 313Cisplatin 271Biopsy 270Radiotherapy 245Paclitaxel 230Gemcitabine 228Bevacizumab 211Nivolumab 188fludarabine 185venetoclax 174Drug Therapy 170Dexamethasone 158Blood Specimen Collection 158Oxaliplatin 155Injections 152Capecitabine 152Fluorouracil 144Docetaxel 142Standard of Care 135Radiosurgery 135Rituximab 125Pemetrexed 118durvalumab 115Leucovorin 108Radiation 107atezolizumab 105

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × efineptakin alfa × 1 year × Clear all
NCT07052305 2026-05-13

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine

Phase 1 Recruiting
24 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Mayo Clinic

Phase 2 Recruiting
54 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡